LifeMD shares ‘significantly undervalued’ versus peers, says B. Riley

B. Riley analyst Kyle Bauser kept a Buy rating on LifeMD with an $11 price target following a transfer of analyst coverage. LifeMD is a direct-to-patient digital health company providing virtual and in-home healthcare, the analyst tells investors in a research note. The firm says that despite a premium growth rate and continued expected margin expansion from the telehealth business, the stock trades at 0.9-times, which is “significantly undervalued” compared to peers.